Murphy, Tracy
Mason, Jacqueline M. http://orcid.org/0009-0009-6151-3444
Leber, Brian
Bray, Mark R.
Chan, Steven M.
Gupta, Vikas http://orcid.org/0000-0002-1419-8607
Khalaf, Dina
Maze, Dawn http://orcid.org/0000-0002-4598-9380
McNamara, Caroline J.
Schimmer, Aaron D. http://orcid.org/0000-0003-4023-3899
Schuh, Andre C.
Sibai, Hassan
Trus, Michael
Valiquette, Debbie
Martin, Kylie
Nguyen, Linh
Li, Xuan
Mak, Tak W.
Minden, Mark D.
Yee, Karen W. L. http://orcid.org/0000-0002-2572-9952
Funding for this research was provided by:
Princess Margaret Cancer Foundation (n/a)
Article History
Received: 25 August 2023
Revised: 23 November 2023
Accepted: 30 November 2023
First Online: 19 December 2023
Competing interests
: The authors declare the following potential conflicts of interest: JMM is an employee of Treadwell Therapeutics. BL was a consultant for AbbVie, Novartis, and Pfizer; and has received speakers’ fees or honoraria from AbbVie, Alexion, Amgen, Astellas, Astex, Bristol Myers Squibb/Celgene, Gilead/KITE, Jazz Pharmaceuticals, Janssen, Novartis, Otsuka, Paladin, Pfizer, Roche, and Treadwell Therapeutics. MRB is a co-founder and an employee of Treadwell Therapeutics. SMC has received research funding from AbbVie, Agios, Bristol Myers Squibb/Celgene, and Servier. VG has received research funding through his institution and honoraria from Novartis; and has served on the advisory board of AbbVie, Bristol Myers Squibb/Celgene, GSK, Incyte, Morphosys, Novartis, and Pfizer. DM has received research support from Bristol Myers Squibb/Celgene, Novartis, PharmaEsentia, and Takeda; has participated in advisory boards and received honoraria from Bristol Myers Squibb/Celgene, Jazz, and Novartis; and has participated in consultancy for Pfizer. ADS has received research funding from Takeda Pharmaceuticals, BMS and Medivir AB, and consulting fees/honorarium from Takeda, Novartis, Jazz, and Otsuka Pharmaceuticals; is named on a patent application for the use of DNT cells to treat AML; and is a member of the Medical and Scientific Advisory Board of the Leukemia and Lymphoma Society of Canada. ACS has consulted for and/or received honoraria from and/or received research support from AbbVie, Agios, Amgen, Astellas, Celgene/BMS, GlycoMimetics, Jazz, Novartis, Paladin, Phebra, Pfizer, Servier, and Teva. MT has received research funding from Jazz. LN is an employee of Treadwell Therapeutics. TWM is a co-founder of Treadwell Therapeutics. KWLY was a consultant for Bristol Myers Squibb/Celgene, F. Hoffmann-La Roche, GSK, Jazz Pharmaceuticals, Novartis, Pfizer, Shattuck Labs, Taiho Oncology, and Takeda; received research funding from Astex Pharmaceuticals, Forma Therapeutics, F. Hoffmann-La Roche, Forma Therapeutics, Genentech, Geron Corporation, Gilead Sciences, Janssen Pharmaceuticals, Jazz Pharmaceuticals, Novartis, Shattuck Labs, and Treadwell Therapeutics; and received honoraria from AbbVie, TaiHo, and Novartis. TM, DK, CJM, HS, DV, KM, XL, and MDM declare no competing interests.